文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

连续流左心室辅助装置植入术后右心衰竭新模型的推导与验证:EUROMACS右心衰竭风险评分

Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score.
PubMed 文献 · Circulation · 2017-08-27

研究基于EUROMACS注册数据,将2988例连续流左心室辅助装置植入患者随机分为推导队列(n=2000)和验证队列(n=988),旨在推导并验证早期右心衰竭风险评分。最终构建了包含5个变量、总分9.5分的EUROMACS-RHF风险评分,推导队列C指数0.70、验证队列0.67,优于既往已知评分和单个超声心动图及血流动力学指标。

要点

  • EUROMACS-RHF评分含5个变量:INTERMACS分级、多种正性肌力药使用、超声示重度右室功能障碍、右房压/肺毛细血管楔压比值、血红蛋白。
  • 推导队列右心衰竭发生率为21.7%,且与更低1年生存率(53% vs 71%)和2年生存率(45% vs 58%)相关。
  • 评分优于既往已知风险评分及单个超声心动图和血流动力学指标,可用于基于风险的个体化评估。

核心结论

  • 新型EUROMACS-RHF风险评分优于目前已知的早期术后右心衰竭风险评分和临床预测指标。
  • 该评分可能有助于对接受心室辅助装置治疗评估的晚期心衰患者进行基于风险的个体化临床评估和管理。

研究设计与样本

  • 研究使用EUROMACS注册数据,纳入接受主流装置连续流左心室辅助装置植入的成年患者2988例。
  • 患者被随机分为推导队列(n=2000)和验证队列(n=988)。
  • 主要结局为早期(<30天)重度术后右心衰竭,定义为需短期或长期右心循环支持、连续正性肌力支持≥14天或一氧化氮通气≥48小时。
  • 次要结局为全因死亡率和重症监护室住院时间。

主要发现

  • 推导队列和验证队列的平均评分分别为2.7±1.9和2.6±2.0(P=0.32)。
  • 推导队列中433例(21.7%)在左心室辅助装置植入后发生右心衰竭,与无右心衰竭患者相比1年生存率(53% vs 71%;P<0.001)和2年生存率(45% vs 58%;P<0.001)更低。
  • 右心衰竭风险从11%(低评分0-2)到43.1%(高评分>4;P<0.0001)。
  • 无右心衰竭与有右心衰竭患者的重症监护室住院时间中位数分别为7天(四分位距4-15天)和24天(四分位距14-38天)(P<0.001)。
  • 复合评分的C指数在推导队列为0.70,在验证队列为0.67。

关键数值与推荐

  • EUROMACS-RHF风险评分共9.5分,包含5个变量:INTERMACS分级、多种正性肌力药使用、超声心动图显示的重度右心室功能障碍、右心房压/肺毛细血管楔压比值、血红蛋白。
  • 评分0-2分对应右心衰竭风险11%,评分>4分对应风险43.1%(P<0.0001)。

临床怎么用

  • 该评分可用于接受心室辅助装置治疗评估的晚期心衰患者,辅助基于风险的个体化临床评估和管理。
  • 评分优于既往已知风险评分及单个超声心动图和血流动力学指标,提示其可作为整合临床变量的风险分层工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the study was to derive and validate a novel risk score for early right-sided heart failure (RHF) after left ventricular assist device implantation. METHODS: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) was used to identify adult patients undergoing continuous-flow left ventricular assist device implantation with mainstream devices. Eligible patients (n=2988) were randomly divided into derivation (n=2000) and validation (n=988) cohorts. The primary outcome was early (<30 days) severe postoperative RHF, defined as receiving short- or long-term right-sided circulatory support, continuous inotropic support for ≥14 days, or nitric oxide ventilation for ≥48 hours. The secondary outcome was all-cause mortality and length of stay in the intensive care unit. Covariates found to be associated with RHF (exploratory univariate P<0.10) were entered into a multivariable logistic regression model. A risk score was then generated using the relative magnitude of the exponential regression model coefficients of independent predictors at the last step after checking for collinearity, likelihood ratio test, c index, and clinical weight at each step. RESULTS: A 9.5-point risk score incorporating 5 variables (Interagency Registry for Mechanically Assisted Circulatory Support class, use of multiple inotropes, severe right ventricular dysfunction on echocardiography, ratio of right atrial/pulmonary capillary wedge pressure, hemoglobin) was created. The mean scores in the derivation and validation cohorts were 2.7±1.9 and 2.6±2.0, respectively (P=0.32). RHF in the derivation cohort occurred in 433 patients (21.7%) after left ventricular assist device implantation and was associated with a lower 1-year (53% versus 71%; P<0.001) and 2-year (45% versus 58%; P<0.001) survival compared with patients without RHF. RHF risk ranged from 11% (low risk score 0-2) to 43.1% (high risk score >4; P<0.0001). Median intensive care unit stay was 7 days (interquartile range, 4-15 days) versus 24 days (interquartile range, 14-38 days) in patients without versus with RHF, respectively (P<0.001). The c index of the composite score was 0.70 in the derivation and 0.67 in the validation cohort. The EUROMACS-RHF risk score outperformed (P<0.0001) previously published scores and known individual echocardiographic and hemodynamic markers of RHF. CONCLUSIONS: This novel EUROMACS-RHF risk score outperformed currently known risk scores and clinical predictors of early postoperative RHF. This novel score may be useful for tailored risk-based clinical assessment and management of patients with advanced HF evaluated for ventricular assist device therapy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Soliman OII, Akin S, Muslem R, et al. Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score. Circulation. 2017. PMID: 28847897. doi:10.1161/CIRCULATIONAHA.117.030543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。